Cargando…

Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies

Detalles Bibliográficos
Autores principales:	Jeras, Jernej, Ugovšek, Sabina, Rehberger Likozar, Andreja, Šebeštjen, Miran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781134/ https://www.ncbi.nlm.nih.gov/pubmed/36547456 http://dx.doi.org/10.3390/jcdd9120460

Ejemplares similares

Influence of lipid-lowering drugs on inflammation: what is yet to be done?
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors
por: Likozar, Andreja Rehberger, et al.
Publicado: (2023)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2022)

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
por: Hrovat, Katja, et al.
Publicado: (2022)

LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2021)

The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
por: Levstek, Tina, et al.
Publicado: (2022)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China()
por: Hu, Da-Yi
Publicado: (2016)

A Risk Prediction Model of Atherosclerotic Cardiovascular Disease in Japan
por: Saito, Isao
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
por: Yun, Yeo-Min
Publicado: (2023)

Social Network Structure and Atherosclerotic Cardiovascular Disease
por: Nishi, Nobuo
Publicado: (2018)

Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment
por: Jigoranu, Raul-Alexandru, et al.
Publicado: (2023)

Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?
por: Wong, Nathan D.
Publicado: (2022)

Pharmacologic modulation of intracellular Na(+) concentration with ranolazine impacts inflammatory response in humans and mice
por: Lenz, Max, et al.
Publicado: (2022)

Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem
por: Gidding, Samuel S., et al.
Publicado: (2019)

SIRT1 and Gender Differences in Atherosclerotic Cardiovascular Disease
por: Shimabukuro, Michio
Publicado: (2020)

Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
por: Parums, Dinah V.
Publicado: (2021)

Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
por: Wong, Nathan D., et al.
Publicado: (2022)

Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology
por: Wong, Nathan D.
Publicado: (2022)

Coronary Artery Calcium in Assessment of Atherosclerotic Cardiovascular Disease Risk and its Role in Primary Prevention
por: Hisamatsu, Takashi, et al.
Publicado: (2023)

Preventing Atherosclerotic Cardiovascular Disease Using American College of Cardiology and American Heart Association Prevention Guidelines: Some Good News, But Caveats Remain
por: Stone, Neil J.
Publicado: (2016)

Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
por: Sikand, Geeta, et al.
Publicado: (2020)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting
por: Tani, Shigemasa
Publicado: (2020)

L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
por: Shimabukuro, Michio
Publicado: (2023)

Magnesium for the prevention and treatment of cardiovascular disease
por: DiNicolantonio, James J, et al.
Publicado: (2018)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

Carotid atherosclerotic disease
por: Sitrângulo, Cid José, et al.
Publicado: (2018)

Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease
por: Yu, En, et al.
Publicado: (2018)

Implication of new atherosclerotic carotid plaques in the cardiovascular outcome of patients with rheumatoid arthritis
por: González-Gay, Miguel A, et al.
Publicado: (2012)

Digital interventions in the treatment of cardiovascular risk factors and atherosclerotic vascular disease
por: Steinmetz, Martin, et al.
Publicado: (2020)

Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
por: German, Charles Amir, et al.
Publicado: (2020)

New Insights in Prevention and Treatment of Cardiovascular Disease
por: Di Raimondo, Domenico, et al.
Publicado: (2022)

Lifestyle management to prevent atherosclerotic cardiovascular disease: evidence and challenges
por: van Trier, T. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s02ih0k63ran06ega2uh20kmsi